$CVM The "Baked In" $ for a successful PH3 Study evaluating the efficacy of Multikine in H&NC, a Potential and Likely Breakthrough in Cancer immunotherapy stands at roughly 7% @$14/sh. In case anyone is curious as to the upside potential here. Market Cap is severely undervalued!!! Tute ownership has heavily increased 1Q 20 and some hedged their bets, absolutely normal, me I'm All In! Go CVM!!!